AOD-9604 vs Tesamorelin
Both AOD-9604 and Tesamorelin are used for fat-loss. Here's how their evidence, dosing, and regulatory status actually compare.
AOD-9604
Evidence C+Anti-Obesity Drug 9604
A modified fragment of human growth hormone (hGH 176-191) that stimulates fat breakdown without the growth-promoting or diabetogenic effects of full HGH.
View full AOD-9604 profile →Tesamorelin
Evidence ATesamorelin (Egrifta)
An FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.
View full Tesamorelin profile →Side-by-Side
| Attribute | AOD-9604 | Tesamorelin |
|---|---|---|
| Evidence Grade | C+ | A |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | FDA-approved for HIV-associated lipodystrophy |
| Typical Dose | 250–500 mcg daily (subcutaneous) | 2 mg daily (subcutaneous) |
| Clinics Indexed | 134 | 178 |
| Categories | weight-loss, fat-loss | growth-hormone, fat-loss |
Key reported benefits — AOD-9604
- ✓Fat metabolism
- ✓No HGH side effects
- ✓Cartilage repair potential
Key reported benefits — Tesamorelin
- ✓Visceral fat reduction
- ✓Natural GH stimulation
- ✓Cognitive benefit
- ✓Lean mass
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.